Guy-Armel Bounda Author
Subjects of specialization
Affiliation
Liver Diseases,Nephrology,Anticoagulation
Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 24# Tong Jia Xiang, Jiangsu Nanjing 210009, P.R. China
I'm an young International Scientist & Researcher. I received my B.Sc. degree and M.Sc. degree in Pharmacy and Clinical Pharmacy, respectively in 2007 and 2010 from China Pharmaceutical University, Jiangsu Nanjing. Afterwards i was awarded a PhD in Clinical Pharmacy, focusing on mechanism of Herbal Medicines and Signaling Pathways in Liver Diseases I ran In-patient and out-patient Anticoagulation Clinic for two years in Nanjing Drum Tower Hospital. . In addition, i gained experience for more than 5 years in Biomedical Equipment from SINOMEDICA CO.LTD (Nanjing) as i had part-time job while i was pursuing my studies. "
Review Article Open Access
Author(s): Ercilia Da Gloria LI, Jian-Xin Lv, Guy-Armel Bounda, Xin-Hua Cao, Hao-Lin Hu and Ya-Nan Zhang* (China)
Breast Cancer (BC) is the most common cancer in women, and second most cancer worldwide. It is a progressive and fatal disease that affects women of all ages, and is divided into several subtypes with distinct histological, genomic and transcriptomic profiles, outcomes, and responses to therapy. Ductal carcinoma in situ (DCIS) is a pre-invasive stage in the development of invasive breast carcinoma. DCIS presents a clinical problem, with high risk of potential progressive disease. A subset of patients with ductal carcinoma in situ (DCIS) will develop Invasive Breast Cancer (IBC). Thus, biomarkers are pivotal important to help identify DCIS/ IBC genes that might probably lead to potential rational treatment therapies. While biomarkers are defined as indicators of normal biological process... view moreĀ»